- Home
- VSNT vs DNTH Comparison
VSNT vs DNTH Comparison
Compare VSNT & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSNT | DNTH |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.5B |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VSNT | DNTH |
|---|---|---|
| Price | $39.20 | $114.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $43.67 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.8M | 751.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $6,688,000,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.48 |
| P/E Ratio | $11.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.17 | $20.71 |
| 52 Week High | $45.58 | $116.47 |
Technical Indicators
Market Signals| Indicator | VSNT | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 60.41 |
| Support Level | $34.95 | $79.27 |
| Resistance Level | $42.17 | N/A |
| Average True Range (ATR) | 1.32 | 5.78 |
| MACD | 0.35 | 0.08 |
| Stochastic Oscillator | 55.48 | 86.86 |
Price Performance
Historical ComparisonAbout VSNT Versant Media Group Inc. Class A Common Stock
Versant Media Group Inc is an independent media company comprised of NBCUniversal's cable television networks, including USA Network, CNBC, MSNBC, Oxygen, SYFY, and Golf Channel, along with complementary digital assets Fandango, Rotten Tomatoes, GolfNow, GolfPass, and SportsEngine.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.